Floatz logo

AMPHOTERICIN

Infection

Medical Research CouncilSmall moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Infection cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
Radboud University Medical Center
Phase 4A
Trimethoprim
Radboud University Medical Center
Phase 4A
Ciprofloxacin
Radboud University Medical Center
Phase 4BBB
FILGRASTIM
Cellerant Therapeutics
Phase 3BB
Aztreonam
Liverpool Heart and Chest Hospital NHS Foundation Trust
Phase 4BB

View all 50 →

Same molecule, other indications

AMPHOTERICIN is also rated in:

Morbid ObesityDormant
B
Indicative ·
62 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
60 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →